Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2014

Intangible Assets

Schedule of intangible assets

	March 31, 2014
(In thousands)	Weighted Average Remaining Amortization Period (Years)	Gross Carrying Value		Accumulated Amortization			Net Carrying Value
FDA approval and launch of BREO® ELLIPTA® in the U.S.	15.4	$	60,000	$	(1,579	)	$	58,421
MHLW approval and launch of RELVAR® ELLIPTA® in Japan	14.7	20,000		(444		)	19,556
European Commission approval and launch of RELVAR® ELLIPTA®	14.8	30,000		(500		)	29,500
FDA approval of ANOROTM ELLIPTATM in the U.S.	15.2	30,000		—			30,000
Total intangible assets		$	140,000	$	(2,523	)	$	137,477

	December 31, 2013
(In thousands)	Weighted Average Remaining Amortization Period (Years)	Gross Carrying Value		Accumulated Amortization			Net Carrying Value
FDA approval and launch of BREO® ELLIPTA® in the U.S.	15.7	$	60,000	$	(632	)	$	59,368
MHLW approval and launch of RELVAR® ELLIPTA® in Japan	14.9	20,000		(111		)	19,889
European Commission approval of RELVAR® ELLIPTA®	15	15,000		—			15,000
FDA approval of ANOROTM ELLIPTATM in the U.S.	15.2	30,000		—			30,000
Total intangible assets		$	125,000	$	(743	)	$	124,257